no doubt that Corona vaccines It was a glimmer of hope for the whole world, as it would put an end to one of the biggest crises of the new century, the emerging virus.
In good news, a French study published on Monday showed that vaccination against Covid-19 reduces the risk of hospitalization and death due to the Corona virus by 90% in those over the age of 50 and appears also effective against the delta mutant.
9 times less
For his part, director of the “IpFar” group and epidemiologist Mahmoud Zureik said, “This means that vaccinated people are nine times less likely to be hospitalized or die from complications from Covid-19 compared to those who are not vaccinated,” according to what he was quoted as saying by AFP.
The researchers in the “Epifar” group reached this conclusion by comparing the data of 11 million vaccinated individuals over the age of 50 years with the data of 11 million people of the same age group but who were not vaccinated, over a period that extended from the first day vaccination began in France, i.e. 27 December 2020 to July 20th.
Low risk of death
The researchers also noted “a decrease in the risk of hospitalization by more than 90%” from the 14th day after the person received his second dose of the Pfizer-Biontech, Moderna or AstraZeneca vaccine. As for the fourth type of vaccine allowed to be used in France, that is, the Jansen vaccine, which was approved for use at a later time, it was used in lesser proportions in France, so it was not included in the study.
The “EpiFar” group also found that “this percentage of the decrease is approximately equivalent to the percentage of the decrease in the risk of death during hospitalization due to Covid-19.”
This appears to be effective on severe forms of COVID-19 “It did not decline during the five-month follow-up period.”
In order to determine the effect of the delta mutated, which affected the most prevalent form of the virus currently, the researchers studied specifically the extent to which the rate of admission to hospital decreased during the period in which it spread heavily in France, starting from June 20, i.e. a month before the end of the study.
They also observed results similar to those of previous time periods: 84% effectiveness in those over the age of 75 and 92% in those aged 50 to 74 years.
However, researchers who are still working on their studies to learn more about the subject, pointed out that these numbers provide “preliminary information”, and “this time period is considered too short to assess the actual impact of vaccination on this mutant.”
This French study confirms other similar conclusions in other regions of the world.